CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

NCT03387592 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

53

Enrollment

OTHER

Sponsor class

Stopped Efficacy endpoint not met according to first step of Briant-Day design

Conditions

Neuroendocrine Carcinoma

Interventions

DRUG: CPT-11
DRUG: Calcio levofolinate
DRUG: 5-Fluorouracil
DRUG: Capecitabine
DRUG: Temozolomide

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS